You have read about TMS. You know it helps people with treatment-resistant depression. And now you are sitting with a question that no amount of research can fully answer: Will it work for me?
That feeling, hope tangled with the fear of being the exception, is something nearly every person in your position has felt. After multiple medications that did not deliver, it makes sense to be cautious about the next thing. This guide is written to replace that uncertainty with a clear picture of what candidacy actually means and what to expect from the evaluation.
Here is what we can tell you honestly: in clinical practice, approximately 50-60% of people with treatment-resistant depression who try TMS experience a meaningful reduction in symptoms, and some real-world settings report response rates as high as 60-70%. Those are among the strongest odds available after failed medication trials. Not a guarantee, but a real chance, backed by evidence.
This guide walks you through the candidacy process, what the evaluation looks like, and how to decide if TMS belongs in your treatment plan. For the science behind how TMS works on the brain, see our guide on why TMS rewires pathways antidepressants cannot reach.
The TRD Profile: Does This Sound Like You?
TMS was designed for exactly the situation most people reading this are in.
Treatment-resistant depression, or TRD, has a specific clinical definition: it means you have tried at least two adequate courses of antidepressant medication (at the right dose, for the right length of time) and your depression either did not improve, improved partially but not enough, or the side effects made it impossible to continue.
In practice, that often looks something like this:
- You started with an SSRI (sertraline, escitalopram, or something similar). It did not move the needle, or it helped briefly then stopped.
- Your prescriber switched you to an SNRI (like venlafaxine or duloxetine), or added an augmentation agent like bupropion or aripiprazole. Some improvement, maybe. Not enough.
- You have tried therapy alongside medication. You have adjusted doses. You have waited the full six to eight weeks each time, hoping the next change would be the one.
If that is your story, or some version of it, you meet the clinical threshold for TRD. And TMS was FDA-cleared specifically for this population.
A few things that do not disqualify you:
- You’re still taking medication. TMS can be done alongside antidepressants. Many members continue their current prescriptions during treatment.
- You’ve had ECT before. Prior electroconvulsive therapy does not rule out TMS candidacy.
- You’ve been in therapy for years. Multiple prior therapies do not work against you. They actually support the case that you need a different approach.
The STAR*D trial, the largest study ever conducted on depression treatment, found that after two failed medication trials, remission rates for a third medication dropped to roughly 12-20%. TMS consistently outperforms that threshold in the treatment-resistant population.
The Candidacy Evaluation: What Nushama Actually Assesses
The evaluation is not a gatekeeping exercise. It is a conversation designed to build the right treatment plan for you, and for most people it removes far more worry than it creates.
At Nushama, the initial assessment typically runs 60 to 90 minutes and can begin with a telehealth appointment. The goal is to understand your full picture: not just your diagnosis, but your treatment history, your current symptoms, and what you are hoping to achieve.
What the Evaluation Covers
- Psychiatric history and current symptoms. Your care team reviews your depression history, including how long you have been living with it, how severe your symptoms are right now, and whether you are managing any co-occurring conditions like anxiety, OCD, or PTSD.
- Medication trial history. This is where specifics matter. Which medications you have tried, at what doses, for how long, and why you stopped. Insurance authorization for TMS typically requires documentation of at least two adequate antidepressant trials.
- Safety screening. TMS uses magnetic pulses near the brain, which means certain medical devices and conditions need to be evaluated. The main contraindications include:
- Active seizure disorder or a history of unprovoked seizures
- Ferromagnetic metal implants in or near the head (cochlear implants, aneurysm clips, deep brain stimulators)
- Certain cardiac devices near the treatment area
Standard dental work, titanium implants elsewhere in the body, and braces are not a concern.
What You’ll Leave With
A clear recommendation. If TMS is appropriate, your care team will outline a treatment plan, including which protocol may suit you (standard or accelerated TMS), how many sessions to expect, and a realistic timeline. (For a feel of what a treatment day itself is like, that is covered in our day-of experience guide, so the evaluation can stay focused on whether TMS is right for you.)
The reassuring part: most people with a treatment-resistant depression history and no medical contraindications are candidates for TMS.
What to Ask at Your Consultation
People who come with questions get more from their consultation and make better decisions. You do not need a background in neuroscience to ask the right things. Here are questions worth bringing.
About your candidacy
- “Based on my medication history, how strong is my candidacy for TMS?”
- “Are there any factors in my history that might affect how well I respond?”
About the protocol
- “Would you recommend standard or accelerated TMS for my situation?”
- “How many sessions are we looking at, and what’s the schedule?”
About outcomes
- “What response rate should I realistically expect given my specific history?”
- “What does a partial response look like? What do you adjust if I’m not responding after a certain number of sessions?”
About logistics
- “Can I continue my current medications during treatment?”
- “What does the follow-up protocol look like after my course is complete?”
- “Is this covered by my insurance, and what documentation is needed?”
One thing worth noting: a good TMS provider welcomes these questions. If a provider seems reluctant to discuss expected outcomes, adjustment protocols, or what happens if treatment does not work, that hesitation is itself useful information.
TMS vs. Other TRD Options: The Honest Comparison
The goal is not to sell you on TMS. It is to help you understand where TMS fits in the landscape of treatment options so you can make an informed choice.
| Option | Typical response | Onset | Key tradeoff |
|---|---|---|---|
| TMS | 50-60% (some settings report 60-70%) | Builds over 2-6 weeks | Non-invasive; mild scalp discomfort or headache |
| ECT | ~70-90% in severe/psychotic depression | Relatively fast | Requires general anesthesia and induced seizures; risk of short-term memory loss |
| Ketamine / Spravato | Rapid relief for many | Sometimes within hours | May require maintenance sessions to sustain |
| Adding a third medication | ~12-20% remission (STAR*D) | 6-8 weeks per trial | Declining odds after two failed trials |
TMS vs. ECT
Electroconvulsive therapy (ECT) has higher initial response rates, roughly 70-90% in severe and psychotic depression, but it requires general anesthesia, involves induced seizures, and carries a meaningful risk of short-term memory loss. Recovery time is also more significant. TMS response rates are lower but still strong (50-60% range), and side effects are typically limited to mild scalp discomfort or headache. For many people, TMS is the right first step, with ECT held in reserve for the most severe or treatment-refractory cases.
TMS vs. Ketamine or Spravato
Both TMS and ketamine therapy work through different mechanisms than traditional antidepressants. Ketamine acts faster, sometimes within hours, while TMS builds its effects over a course of weeks. TMS may offer more durable effects after a full treatment course, while ketamine’s benefits may require maintenance sessions to sustain. Many people benefit from doing both, either sequentially or as part of an integrated treatment plan.
TMS vs. Adding Another Medication
The STAR*D trial found that after two failed antidepressant trials, remission rates for a third medication dropped to roughly 12-20%. TMS consistently exceeds those numbers in the treatment-resistant population. For many people at this stage, a non-medication approach may offer better odds than another pharmaceutical trial.
We want to be straightforward: not everyone responds to TMS. At Nushama, we monitor outcomes throughout treatment and discuss next steps openly if the response is not what we are hoping for. For some members, that means combining TMS with ketamine therapy. For others, it means exploring different protocols or alternative approaches.
What a Good Response to TMS Actually Looks Like
Response is not always dramatic, and that is okay. For most people, it starts quietly.
The Numbers
Research consistently shows that approximately 50-60% of people with TRD experience a meaningful response to TMS, with some clinical settings reporting response rates of 60-70% and remission rates of 30-40%.
What “Meaningful Response” Looks Like in Daily Life
It rarely arrives as a single moment of clarity. More often, members notice they are sleeping a little better, or that they got through a full workday without the weight pressing down. They realize they laughed at something their kid said and did not have to force it. Over time, these quiet shifts accumulate into something significant. Many people are able to reduce their medication doses. Some discontinue antidepressants entirely, with their prescriber’s guidance.
Partial Response and What Comes Next
Some people improve meaningfully but do not reach full remission. At Nushama, that is not the end of the conversation. Options may include booster TMS sessions, a shift to a different protocol, or combining TMS with ketamine-assisted therapy to address different aspects of the depression.
Timeline
Response typically builds over two to six weeks after the treatment course. Some members notice early shifts during treatment itself (changes in energy, sleep quality, or emotional reactivity) while the fuller antidepressant effect develops more gradually.
Honesty About Non-Response
Roughly 30-40% of people with TRD do not respond to a first TMS course. That is a real number, and we think you deserve to know it upfront. If that happens, Nushama discusses next steps transparently, whether that is a different TMS approach, ketamine therapy, or a referral to another specialist.
Frequently Asked Questions
Can I get TMS if I’m still taking antidepressants?
Yes. TMS is commonly used alongside existing medications. Your care team will review your current prescriptions during the evaluation to make sure there are no interactions that need to be managed. Nushama also offers medication management as part of an integrated treatment approach.
How long does a TMS evaluation take?
Initial assessments at Nushama typically run 60 to 90 minutes. In some cases, the first conversation can happen via telehealth, with in-person assessment following. Book a consultation to get started.
What are the most common side effects of TMS?
The most frequently reported side effects are mild scalp discomfort and headache during or after treatment sessions. These tend to diminish over the first few sessions. Serious side effects, such as seizures, are extremely rare (less than 0.1% of cases). For a deeper look at how TMS compares to antidepressant side effects, see our guide on accelerated TMS vs. antidepressants.
How soon will I know if TMS is working?
Most people begin to notice changes within two to four weeks of starting treatment, though the full effect often develops over six weeks or more. Your care team will track your progress using validated assessment tools throughout the course. Learn more about how TMS works on treatment-resistant depression.
The evaluation is the step that turns uncertainty into a plan. Whether TMS is right for you or not, the consultation gives you a clear answer, and that clarity has value regardless of the outcome. You have spent enough time wondering. A conversation with our care team can help you move from questions to a decision that makes sense for your life.
